The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | MRD-guided therapy in multiple myeloma
Benjamin Derman, MD, The University of Chicago, Chicago, IL, discusses measurable residual disease (MRD)-guided therapy in multiple myeloma, highlighting key clinical trials using MRD to guide discontinuation of maintenance therapy and explaining the importance of better understanding how to both escalate and de-escalate therapy in patients. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Honoraria for advisory board fees from Janssen, Sanofi, and COTA healthcare.
